About
mRNA-Engineered Cell Therapy
Areas of Focus
Categories
Stem Cell & Cellular TherapyVirginia, DC, DE & Maryland
Team (26)
Andrés J. García, PhD
Cartesian Therapeutics
team_member
Blaine Davis
Chief Financial Officer
Cartesian Therapeutics
executive
Carolina Barnett-Tapia, MD
Cartesian Therapeutics
team_member
Carrie S. Cox, Chairman
Cartesian Therapeutics
team_member
Carsten Brunn, PhD
President and Chief Executive Officer
Cartesian Therapeutics
executive
Chris Jewell, PhD
Chief Scientific Officer
Cartesian Therapeutics
executive
Clinical Trials (11)
View allTotal Trials
11
As Lead Sponsor
11
As Collaborator
0
Total Enrollment
305
By Phase
PHASE1/PHASE2: 1PHASE3: 1PHASE1: 5PHASE2: 4
By Status
TERMINATED: 5RECRUITING: 2ACTIVE_NOT_RECRUITING: 2NOT_YET_RECRUITING: 1COMPLETED: 1
Clinical Trials Pipeline11 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
Today
Hover over trial bars to see details
Recent Trials
NCT07089121Lead Sponsor
Descartes-08 for Children, Adolescents and Young Adults With Childhood-onset Systemic Lupus Erythematosus, ANCA-associated Vasculitis, Juvenile Myasthenia Gravis, and Juvenile Dermatomyositis
PHASE1/PHASE2Not yet recruiting
50 participants
Started: Dec 31, 2025 · Completed: Dec 31, 2026
NCT06799247Lead Sponsor
Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia Gravis
PHASE3Recruiting
100 participants
Started: May 6, 2025 · Completed: Sep 30, 2027
NCT06304636Lead Sponsor
Descartes-15 for Patients With Relapsed/Refractory Multiple Myeloma
PHASE1Active, not recruiting
4 participants
Started: Jun 19, 2024 · Completed: Oct 1, 2027
NCT06038474Lead Sponsor
Descartes-08 for Patients With Systemic Lupus Erythematosus
PHASE2Recruiting
30 participants
Started: Feb 12, 2024 · Completed: Nov 1, 2026
NCT04816526Lead Sponsor
Descartes-08 Consolidation Treatment in Patients With High-Risk Multiple Myeloma High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy
PHASE2Terminated
13 participants
Started: Dec 1, 2021 · Completed: Nov 3, 2022
Locations (1)
Headquarters
Gaithersburg, MD, United States
Map
Loading map...